Calaspargase Pegol-mknl Granted FDA Approval for Pediatric, Young Adult Patients With ALL
December 21st 2018The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients, aged 1 month to 21 years.
Read More
FDA Approves Calaspargase Pegol-mknl for Young Patients With ALL
December 21st 2018The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients
Read More